Clinical Trials

330 enrolled

Small Cell Lung Carcinoma

NCT07226999 2026-06-04

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

Phase 2/3 Recruiting

550 enrolled

Small Cell Lung Carcinoma

NCT07476287 2026-06-04

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Phase 2 Recruiting

40 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07488676 2026-06-04

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Phase 1/2 Recruiting

150 enrolled

GastrointestinalThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT07559019 2026-06-04

Safety and Preliminary Activity of BI115 in Advanced SCLC

150 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

550 enrolled

Phase 1 Not yet recruiting

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT07623369 2026-06-03

A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

56 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07623642 2026-06-03

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Phase 2 Not yet recruiting

227 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Gallbladder Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06203210 2026-06-02

IDeate-Lung02

540 enrolled

Small Cell Lung Carcinoma

NCT06936735 2026-06-02

A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors

502 enrolled

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT07046923 2026-06-02

A Study of LY4175408 in Participants With Advanced Cancer

BreastGynecologicThoracic

240 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07454642 2026-06-02

FOCUS-01

174 enrolled

GastrointestinalThoracic

Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT07472517 2026-06-02

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

670 enrolled

Phase 1/2 Active not recruiting

Small Cell Lung Carcinoma

NCT04938817 2026-06-01

KEYNOTE-B98

110 enrolled

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT05783622 2026-06-01

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

130 enrolled

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06646276 2026-06-01

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

530 enrolled

Small Cell Lung Carcinoma

NCT06712355 2026-06-01

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

621 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07124000 2026-06-01

DP-04

Recruiting

100 enrolled

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT06598306 2026-05-29

DeLLphi-308

220 enrolled

Small Cell Lung Carcinoma

NCT07531095 2026-05-29

DeLLphi-313

160 enrolled

Phase 1/2 Not yet recruiting

Small Cell Lung Carcinoma

NCT07559929 2026-05-29

A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.

200 enrolled

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT06077500 2026-05-27

DAREONᵀᴹ-8

46 enrolled

Small Cell Lung Carcinoma

NCT07099898 2026-05-27

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

420 enrolled

Phase 2 Not yet recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07459634 2026-05-27

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

50 enrolled

Small Cell Lung Carcinoma

NCT07564401 2026-05-27

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

Phase 1/2 Recruiting

80 enrolled

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

NCT04624204 2026-05-26

MK 7339-013

672 enrolled

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT06612151 2026-05-26

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

438 enrolled